Search Result

Results for "

hepatoma carcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (7) Autophagy (1) Bacterial (3) Bcl-2 Family (3) Caspase (2) Cathepsin (1) CDK (2) CXCR (1) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) Drug Derivative (1) Endogenous Metabolite (1) ERK (2) Ferroptosis (2) Fungal (1) Glutathione Peroxidase (1) Glutathione S-transferase (1) HBV (1) HCV (1) HSP (1) IFNAR (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (1) MEK (1) Microtubule/Tubulin (1) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) Parasite (1) PARP (1) Pyroptosis (1) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (3) TrxR (1) Tyrosinase (1)
By Research Areas:	Cancer (16) Infection (4) Inflammation/Immunology (3)

By Targets:

Apoptosis (7)

Autophagy (1)

Bacterial (3)

Bcl-2 Family (3)

Caspase (2)

Cathepsin (1)

CDK (2)

CXCR (1)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (1)

Drug Derivative (1)

Endogenous Metabolite (1)

ERK (2)

Ferroptosis (2)

Fungal (1)

Glutathione Peroxidase (1)

Glutathione S-transferase (1)

HBV (1)

HCV (1)

HSP (1)

IFNAR (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JNK (1)

MEK (1)

Microtubule/Tubulin (1)

mTOR (1)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

Parasite (1)

PARP (1)

Pyroptosis (1)

Raf (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (1)

STAT (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

Topoisomerase (3)

TrxR (1)

Tyrosinase (1)

By Research Areas:

Cancer (16)

Infection (4)

Inflammation/Immunology (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-N0095

(S)-10-Hydroxycamptothecin 1 Publications Verification 10-HCPT; 10-Hydroxycamptothecin	Topoisomerase Apoptosis	Cancer
(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment .

HY-N6674

Diazepinomicin ECO-4601; TLN-4601; BU 4664L	Apoptosis Bacterial Cathepsin Parasite Endogenous Metabolite	Infection Inflammation/Immunology Cancer
Diazepinomicin (ECO-4601) is an anticancer and antibacterial agent. Diazepinomicin can be produced by a Micromonospora strain. Diazepinomicin induces Apoptosis. Diazepinomicin inhibits the proteases Rhodesain and Cathepsin L at an IC₅₀ of 70-90 μM. Diazepinomicin possesses anti-inflammatory and anti-tumor activity. Diazepinomicin has demonstrated activity against hepatocellular carcinoma. Diazepinomicin shows antiparasitic activity against trypomastigote forms of Trypanosoma brucei with an IC₅₀ of 13.5 μM. Diazepinomicin exhibits moderate antibacterial activity against specific Gram-positive bacteria, with an MIC of approximately 32 μg/mL .

HY-N11546

Sapindoside B	Cytochrome P450 Bacterial Fungal	Infection Cancer
Sapindoside B is a substance with hepatoprotective activity, and also acts as a cytochrome P-450 (cytochrome P-450) inhibitor, antibacterial agent and membrane-disrupting agent. Sapindoside B reversibly inhibits the content of cytochrome P-450 in liver microsomes, suppresses the phenobarbital-induced increase in enzyme content, reduces the production of active metabolites mediated by cytochrome P-450, and alleviates hepatotoxic injury. Sapindoside B binds to Cutibacterium acnes lipase, reduces lipase activity, inhibits biofilm formation, and decreases bacterial adhesion. Sapindoside B exhibits cytotoxicity against human cancer, liver cancer, leukemia and glioblastoma cells. Sapindoside B inhibits mycelial growth of phytopathogenic fungal strains, possesses antibacterial activity against dermatophytes, and also has hemolytic/membrane-lytic activity. Sapindoside B can be used in research related to liver injury, Cutibacterium acnes biofilm-associated infections, gastric cancer, carcinoma, promyelocytic leukemia, glioblastoma, apple scab and grape gray mold .

HY-158058

WYJ-2	Toll-like Receptor (TLR) Pyroptosis	Inflammation/Immunology Cancer
WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC₅₀ of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC) .

HY-N3665

Cyclocommunol	Tyrosinase	Cancer
Cyclocommunol is a prenylflavonoid with antityrosinase and antiplatelet activitie, can be solated from breadfruit. Cyclocommunol exerts anti-tumor activity and inhibits the growth of human hepatoma and gastric cancer cells with IC₅₀ values between 16 and 80 µM. Cyclocommunol shows proapoptotic effect on oral squamous cell carcinoma (OSCC) .

HY-N0095S

(S)-10-Hydroxycamptothecin-d5 10-HCPT-d₅; 10-Hydroxycamptothecin-d₅	Isotope-Labeled Compounds Apoptosis Topoisomerase	Cancer
(S)-10-Hydroxycamptothecin-d₅ (10-HCPT-d₅) is the deuterium labeled (S)-10-Hydroxycamptothecin. (S)-10-Hydroxycamptothecin (10-HCPT) is a DNA topoisomerase I inhibitor. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia research .

HY-N0095R

(S)-10-Hydroxycamptothecin (Standard) 10-HCPT (Standard); 10-Hydroxycamptothecin (Standard)	Reference Standards Topoisomerase Apoptosis	Cancer
(S)-10-Hydroxycamptothecin (Standard) is the analytical standard of (S)-10-Hydroxycamptothecin. This product is intended for research and analytical applications. (S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment .

HY-N1183

Taiwanhomoflavone A	Others	Cancer
Taiwanhomoflavone A is a C-methylated biflavone, that can be isolated from the stem of Cephalotaxus wilsoniana. Taiwanhomoflavone-A shows anticancer activity .

HY-P10832

ATWLPPRAANLLMAAS	Apoptosis Ras Raf MEK ERK Caspase PARP Bcl-2 Family	Cancer
ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis. .

HY-173387

4F-Docetaxel 4FDT	Drug Derivative	Cancer
4F-Docetaxel (4FDT) is a fluorinated docetaxel analog. 4F-Docetaxel has anti-hepatoma activity and can be used for research of hepatocellular carcinoma (HCC) .

HY-183554

Fa-Au	TrxR Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS) IFNAR STAT	Cancer
Fa-Au is a TrxR inhibitor. Fa-Au downregulates GPX4, induces oxidative stress, mitochondria-associated ferroptosis (ferroptosis) and immunogenic cell death. Fa-Au induces ROS production in hepatoma cells. Fa-Au remodels the tumor immune microenvironment via M1 macrophage polarization, dendritic cell maturation, CD8+ T cell activation and reduction of regulatory T cells. Fa-Au induces an anti-tumor immune feedback loop through the IFNγ/STAT1/SLC7A11 axis. Fa-Au inhibits tumor growth. Fa-Au is applicable to hepatocellular carcinoma-related research .

HY-N8013

5-O,8-Dimethylophiopogonanone B	Others	Cancer
5-O,8-Dimethylophiopogonanone B is a homoisoflavanone found in the tuberous roots of Ophiopogon japonicus. 5-O,8-Dimethylophiopogonanone B shows cytotoxicity against cancer cells. 5-O,8-Dimethylophiopogonanone B can be used for the research of cancer, such as breast cancer .

HY-133151

CXCR6 antagonist 1	CXCR	Cancer
CXCR6 antagonist 1 (Compound 81) is an orally active CXCR6 antagonist. CXCR6 antagonist 1 inhibits the CXCR6 receptor signaling pathway, including β-arrestin recruitment and Forskolin (HY-15371)-induced cAMP production. CXCR6 antagonist 1 reduces tumor growth in a mouse xenograft model of hepatocellular carcinoma. CXCR6 antagonist 1 can be used in research related to hepatocellular carcinoma .

HY-W705093

Dimethoxane	Bacterial	Infection Cancer
Dimethoxane is an antibacterial agent and an orally active oncogen. Dimethoxane exerts slow bactericidal action against various bacteria, rapid bacteriostatic action that halts bacterial growth, and does not induce bacterial lysis. Dimethoxane induces multiple tumor formation in rats. Dimethoxane functions as a low-toxicity preservative in cosmetic formulations and controls spoilage microorganisms in aqueous systems, emulsions, and suspensions .

HY-P991883

Metuzumab Licartin; Metuximab; Mehuzumab	Apoptosis CDK Caspase Bcl-2 Family	Cancer
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2]_.

Cat. No.	Product Name

HY-L101

Anti-Liver Cancer Compound Library	2,872 compounds
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers. Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc. MCE offers a unique collection of 2,872 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Anti-Liver Cancer Compound Library

2,872 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,872 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area